HieraBio

HieraBio is a pre-clinical biotechnology company focused on the de novo design of protein therapeutics to treat inflammatory and autoimmune diseases. Leveraging technology developed at the University of Washington's Institute for Protein Design, the company employs a hierarchical design approach to create synthetic proteins with precise geometry and function. Their platform enables the development of smart biologics that can respond to specific physiological cues, potentially improving safety and efficacy over traditional therapies. HieraBio is currently advancing a pipeline of novel protein candidates designed to modulate key immune pathways such as cytokine signaling. The company is headquartered in Seattle and is backed by prominent venture capital investors including Madrona Venture Group.